Medical Oncology

ASCO 2021

Questions discussed in this category

Should we start performing universal germline mutation testing for all newly diagnosed breast cancer?

Given OlympiA trial with olaparib benefit for gBRCA+ patients?What are barriers that you foresee? In your practice who performs mutation testing and w...

5 Answers available

Will you offer adjuvant olaparib to patients with somatic BRCA mutated breast cancer given that OlympiA only enrolled germline BRCA+?

Do you perceive a difference between somatic vs germline BRCA mutations?

2 Answers available

How do you sequence capecitabine and olaparib, if at all, in patients with BRCA+ TNBC and residual disease after neoadjuvant chemotherapy?

5 Answers available

Would you give adjuvant immunotherapy after nephrectomy?

Is DFS benefit in KN-564 in ASCO2021 sufficient evidence to change practice?

1 Answer available

How would you sequence 177LU-PSMA-617 with current therapies for men with mCRPC?

2 Answers available

What strategies have you found to be most effective in engaging PCPs in a primary-care or shared-care model of survivorship for pediatric and AYA patients who will receive ongoing care in their communities away from their primary oncology treatment site?

In follow up to @Jacqueline Casillas presentation at ASCO 2021 regarding models of survivorship care delivery for AYA patients.

1 Answer available

In what scenario would you give consolidation chemotherapy after chemoradiation for stage 3 cervical cancer with a good response?

3 Answers available

How will you decide among the options of either carbo/gem>avelumab or checkpoint monotherapy for cisplatin-ineligible PD-L1 expressing urothelial carcinoma?

Given long term data from Keynote 052 for pembrolizumab presented at ASCO 2021. What factors impact your treatment decisions? For cis-ineligible PD-...

1 Answer available

Papers discussed in this category

J. Clin. Oncol., 2011 Mar 28

Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.

BMC Cancer, 2017 Apr 28

Long-term results of early adjuvant concurrent chemoradiotherapy for high-risk, early stage uterine cervical cancer patients after radical hysterectomy.

The New England journal of medicine, 2016-12-08

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

J Clin Oncol, 2020 Jun 17

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.

J Clin Oncol, 2020 Oct 29

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.

N Engl J Med, 2021 Jun 03

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Ann Surg Oncol, 2019 Jul 24

Consensus Guidelines on Genetic` Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons.

J Clin Oncol, 2020 Mar 03

Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-02-20

Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019-08-20

Should All Patients With a Diagnosis of Breast Cancer Undergo Expanded Panel Testing?

Cancer, 2021 Mar 15

Germline genetic testing in breast cancer: Rationale for the testing of all women diagnosed by the age of 60 years and for risk-based testing of those older than 60 years.

J Clin Oncol, 2015 Nov 1

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Jan 04

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.

N. Engl. J. Med.,

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

N. Engl. J. Med., 2017 Jun 04

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

Annals of oncology : official journal of the European Society for Medical Oncology, 2019-04-01

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.

BMC Cancer, 2018 Mar 07

Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.

N Engl J Med,

Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.

JCO Oncol Pract, 2022 Jan 07

Q and A: A New Standard of Care for Germline and/or Mutation Carriers With Early-Stage Breast Cancer.

Related Topics in Medical Oncology